Topoisomerase enzymes facilitate gene transcription by resolving DNA tangles. Malfunction of these enzymes seems to compromise the expression of very long genes, potentially mediating neurodevelopmental disorders. See Article p.58
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
A Conceptual Model of Angelman Syndrome and Review of Relevant Clinical Outcomes Assessments (COAs)
The Patient - Patient-Centered Outcomes Research Open Access 10 July 2018
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Notes
*This article and the paper under discussion1 were published online on 28 August 2013.
References
King, I. F. et al. Nature 501, 58–62 (2013).
Kishino, T., Lalande, M. & Wagstaff, J. Nature Genet. 15, 70–73 (1997).10.1038/ng0197-70
Huang, H.-S. et al. Nature 481, 185–189 (2011).
Neale, B. M. et al. Nature 485, 242–245 (2012).
Iossifov, I. et al. Neuron 74, 285–299 (2012).
Joshi, R. S., Piña, B. & Roca, J. Nucleic Acids Res. 40, 7907–7915 (2012).
Peter, B. J. et al. Genome Biol. 5, R87 (2004).
Kouzine, F., Sanford, S., Elisha-Feil, Z. & Levens, D. Nature Struct. Mol. Biol. 15, 146–154 (2008).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Plasschaert, R., Bartolomei, M. A long genetic explanation. Nature 501, 36–37 (2013). https://doi.org/10.1038/nature12553
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature12553
This article is cited by
-
A Conceptual Model of Angelman Syndrome and Review of Relevant Clinical Outcomes Assessments (COAs)
The Patient - Patient-Centered Outcomes Research (2019)
-
Pharmacological therapies for Angelman syndrome
Wiener Medizinische Wochenschrift (2017)